In a move that at least one local HIV charity has deemed “profoundly disappointing,” England's health technology assessor NICE is currently recommending against coverage of Gilead Sciences’ landmark ...

See more of our trusted coverage when you search. Prefer Newsweek on Google to see more of our trusted coverage when you search. A new pre-exposure prophylaxis (PrEP) drug has shown promise as a ...

A national health task force’s sterling new endorsement of a long-acting injectable medication for use as HIV prevention will require health insurers to begin covering the pricey drug by 2025. Such ...

Add Yahoo as a preferred source to see more of our stories on Google. This acquisition marks Gilead's first entry into the field of T-cell engagers. Credit: Tada Images / Shutterstock.com. Gilead ...

It’s possible to produce a generic version of lenacapavir, a twice-yearly antiretroviral injection that both prevents and treats HIV, for as little as $25 per patient per year, according to a study ...

When Nicklaus Chalk started law school at the University of California, Berkeley, last fall, one of his top priorities was to take care of his health. The 24-year-old student visited a doctor to get a ...

A Gilead Sciences drug that protects against HIV infection has won a highly anticipated FDA approval, becoming the first medication for HIV prevention available as a twice-yearly injection. The ...

During a routine doctor's visit in 2015, I approached my medical provider about prescribing preexposure prophylaxis, or PrEP, to me to reduce my risk of acquiring HIV. She had no idea what I was ...

After nearly a decade of working as an advocate for HIV and AIDS treatment, Michael Chancley said he came to a sobering realization. “Seeing that people who look like me, who hang out at the same ...

Are you taking PrEP for HIV prevention and wondering if a night at the club is going to affect your medication? Or are you someone interested in getting on PrEP but nervous about how it might interact ...